Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

WADA Peptides Banned Competition Status — Comparison Table

Growth Hormone Secretagogues GHRP-2, GHRP-6, hexarelin, ipamorelin, CJC-1295 S2 (Peptide Hormones) 24–48 hours (short-acting); 28–35 days (depot forms) Rarely granted; requires documented treatment failure with somatropin Most commonly detected peptide class i

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Growth Hormone Secretagogues
  • GHRP-2, GHRP-6, hexarelin, ipamorelin, CJC-1295
  • S2 (Peptide Hormones)
  • 24–48 hours (short-acting); 28–35 days (depot forms)
  • Rarely granted; requires documented treatment failure with somatropin
  • Most commonly detected peptide class in competitive sport; athletes frequently miscalculate depot form persistence
  • Myostatin Inhibitors
  • Follistatin-344, ACE-031, SRK-015
  • S2 (Growth Factors)
  • No direct threshold; biomarker panel detection (elevated serum follistatin + suppressed myostatin)
  • Not available. No approved therapeutic use
  • Indirect detection methodology as of 2026; compliance gap for athletes unaware of biomarker testing
  • GLP-1 Receptor Agonists
  • Semaglutide, tirzepatide, liraglutide
  • S4 (Hormone/Metabolic Modulators)
  • 35–42 days (semaglutide); 28–32 days (tirzepatide)
  • Available for documented obesity/diabetes with failed first-line therapies
  • Newly prohibited in 2026; endurance athletes most affected; retroactive TUEs no longer granted
  • Peptide Fragments with Biological Activity
  • BPC-157, TB-500 (Thymosin Beta-4 fragment)
  • S0 (Non-Approved Substances)
  • 7–10 days (BPC-157); 14–21 days (TB-500)
  • Not available. No regulatory approval
  • S0 classification triggers automatic four-year sanctions; no medical defence pathway
  • IGF-1 and Analogues
  • IGF-1 LR3, DES(1-3) IGF-1
  • 48–72 hours (IGF-1); 5–7 days (long-acting analogues)
  • Rarely granted; limited to severe growth hormone insensitivity syndromes
  • Detection improved significantly in 2025 with new immunoassay kits; athletes who previously evaded testing now face higher AAF risk